Ekso Bionics shares rise 27.81% premarket after securing exclusive U.S. distribution deal for MediTouch's BalanceTutor rehabilitation system.

Ekso Bionics surged 27.81% in premarket trading following the announcement that it secured an exclusive U.S. distribution agreement for MediTouch’s BalanceTutor rehabilitation system. The BalanceTutor, a 4D perturbation treadmill designed to simulate balance challenges for patients, aligns with Ekso’s focus on medical exoskeleton technology. The partnership, described as synergistic by CEO Scott Davis, expands Ekso’s product offerings and market reach in rehabilitation solutions. Investors reacted strongly to the news, with the stock’s premarket gain exceeding the 20% rise noted in prior reporting. The deal underscores Ekso’s strategy to leverage complementary technologies within its enterprise health portfolio, enhancing its competitive position in the medical robotics sector.